Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Improving Neurological Function: A Multicenter, Cluster-Randomized Trial (GIANT)

Xuting Zhang, Wansi Zhong, Xiaodong Ma, Xiaoling Zhang, Hongfang Chen, Zhimin Wang, Min Lou, Xuting Zhang, Wansi Zhong, Xiaodong Ma, Xiaoling Zhang, Hongfang Chen, Zhimin Wang, Min Lou

Abstract

Background and Purpose: We aimed to investigate the effect of Ginkgolide® treatment on neurological function in patients receiving intravenous (IV) recombinant tissue plasminogen activator (rt-PA). Methods: This cluster randomized controlled trial included acute ischemic stroke patients in 24 centers randomized to intervention of intravenous Ginkgolide® or control group within the first 24 h after IV rt-PA therapy (IVT). Clinical outcome at 90 days was assessed with modified Rankin Scale (mRS) score and dichotomized into good outcome (0-2) and poor outcome (3-6). Hemorrhagic transformation represented the conversion of a bland infarction into an area of hemorrhage by computed tomography. Symptomatic intracerebral hemorrhage (sICH) was defined as cerebral hemorrhagic transformation in combination with clinical deterioration of National Institutes of Health Stroke Scale (NIHSS) score ≥4 points at 7-day or if the hemorrhage was likely to be the cause of the clinical deterioration. We performed logistic regression analysis and propensity score matching analysis to investigate the impact of Ginkgolide® treatment with IV rt-PA on good outcome, hemorrhagic transformation and sICH, respectively. Results: A total of 1113 patients were finally included and 513 (46.1%) were in the intervention group. Patients in the Ginkgolide® group were more likely to have good outcomes (78.6 vs. 66.7%, p < 0.01) and lower rate of sICH (0 vs. 2.72%, p < 0.01), compared with patients in the control group. The intra-cluster correlation coefficient (ICC) for good outcome at 90 days was 0.033. Binary logistic regression analysis revealed that treatment with Ginkgolide® was independently associated with 90-day mRS in patients with IV rt-PA therapy (OR 1.498; 95% CI 1.006-2.029, p = 0.009). After propensity score matching, conditional logistic regression showed intervention with Ginkgolide® was significantly associated with 90-day good outcome (OR 1.513; 95% CI 1.073-2.132, p = 0.018). No significant difference in hemorrhage transformation was seen between the 2 matched cohorts (OR 0.885; 95% CI 0.450-1.741, p = 0.724). Conclusion: Using Ginkgolide® within 24-hour after IV rt-PA is effective and safe and might be recommended in combination with rtPA therapy in acute ischemic stroke. Clinical Trial Registration: http://www.clinicaltrials.gov, identifier NCT03772847.

Keywords: Ginkgolide®; improve; intravenous alteplase; prognosis; stroke.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Zhong, Ma, Zhang, Chen, Wang, Lou and GIANT Investigators.

Figures

FIGURE 1
FIGURE 1
Flow of hospitals and patients through the study.
FIGURE 2
FIGURE 2
Distribution of Modified Rankin Scores at 90 days Among Eligible Patients with Ginkgolide intervention vs. Control Group.

References

    1. Bone K. M. (2008). Potential Interaction of Ginkgo Biloba Leaf With Antiplatelet or Anticoagulant Drugs: what Is the Evidence? Mol. Nutr. Food Res. 52, 764–771. 10.1002/mnfr.200700098
    1. Chen Z., Bai S., Hu Q., Shen P., Wang T., Liang Z., et al. (2018). Ginkgo Biloba Extract and its Diterpene Ginkgolide Constituents Ameliorate the Metabolic Disturbances Caused by Recombinant Tissue Plasminogen Activator in Rat Prefrontal Cortex. Neuropsychiatr. Dis. Treat. 14, 1755–1772. 10.2147/NDT.S167448
    1. Collaboration F. T. (2019). Effects of Fluoxetine on Functional Outcomes After Acute Stroke (Focus): a Pragmatic, Double-Blind, Randomised, Controlled Trial. Lancet. 393, 265–274. 10.1016/S0140-6736(18)32823-X
    1. Dong Y., Zhang J., Wang Y., Zhao L., Li R., Wei C., et al. GISAA committee (2021). Effect of Ginkgolide in Ischemic Stroke Patients With Large Artery Atherosclerosis: Results From a Randomized Trial. CNS Neurosci. Ther. 00, 1–9. 10.1111/cns.13742
    1. Fang W., Sha L., Kodithuwakku N. D., Wei J., Zhang R., Han D., et al. (2015). Attenuated Blood-Brain Barrier Dysfunction by XQ-1H Following Ischemic Stroke in Hyperlipidemic Rats. Mol. Neurobiol. 52, 162–175. 10.1007/s12035-014-8851-1
    1. Feng Z., Sun Q., Chen W., Bai Y., Hu D., Xie X. (2019). The Neuroprotective Mechanisms of Ginkgolides and Bilobalide in Cerebral Ischemic Injury: a Literature Review. Mol. Med. 25 (1), 57. 10.1186/s10020-019-0125-y
    1. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., et al. (1998). Randomised Double-Blind Placebo-Controlled Trial of Thrombolytic Therapy With Intravenous Alteplase in Acute Ischaemic Stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 352 (9136), 1245–1251. 10.1016/s0140-6736(98)08020-9
    1. Huang M., Qian Y., Guan T., Huang L., Tang X., Li Y. (2012). Different Neuroprotective Responses of Ginkgolide B and Bilobalide, the Two Ginkgo Components, in Ischemic Rats With Hyperglycemia. Eur. J. Pharmacol. 677, 71–76. 10.1016/j.ejphar.2011.12.011
    1. Hussein H. M., Saleem M. A., Qureshi A. I. (2018). Rates and Predictors of Futile Recanalization in Patients Undergoing Endovascular Treatment in a Multicenter Clinical Trial. Neuroradiology. 60 (5), 557–563. 10.1007/s00234-018-2016-2
    1. Jiang M., Li J., Peng Q., Liu Y., Liu W., Luo C., et al. (2014). Neuroprotective Effects of Bilobalide on Cerebral Ischemia and Reperfusion Injury Are Associated With Inhibition of Pro-inflammatory Mediator Production and Down-Regulation of JNK1/2 and P38 MAPK Activation. J. Neuroinflammation. 11, 167. 10.1186/s12974-014-0167-6
    1. Joseph R., Welch K. M., D'Andrea G. (1989). Effect of Therapy on Platelet Activating Factor-Induced Aggregation in Acute Stroke. Stroke. 20 (5), 609–611. 10.1161/01.str.20.5.609
    1. Knecht T., Borlongan C., Dela Peña I. (2018). Combination Therapy for Ischemic Stroke: Novel Approaches to Lengthen Therapeutic Window of Tissue Plasminogen Activator. Brain Circ. 4 (3), 99–108. 10.4103/bc.bc_21_18
    1. Koch E. (2005). Inhibition of Platelet Activating Factor (PAF)-Induced Aggregation of Human Thrombocytes by Ginkgolides: Considerations on Possible Bleeding Complications After Oral Intake of Ginkgo Biloba Extracts. Phytomedicine. 12 (1-2), 10–16. 10.1016/j.phymed.2004.02.002
    1. Li L., Zhang Q. G., Lai L. Y., Wen X. J., Zheng T., Cheung C. W., et al. (2013). Neuroprotective Effect of Ginkgolide B on Bupivacaine-Induced Apoptosis in SH-Sy5y Cells. Oxid Med. Cell Longev. 2013, 159864. 10.1155/2013/159864
    1. Li P., Stetler R. A., Leak R. K., Shi Y., Li Y., Yu W., et al. (2018). Oxidative Stress and DNA Damage After Cerebral Ischemia: Potential Therapeutic Targets to Repair the Genome and Improve Stroke Recovery. Neuropharmacology. 134, 208–217. 10.1016/j.neuropharm.2017.11.011
    1. Liu Q., Jin Z., Xu Z., Yang H., Li L., Li G., et al. (2019). Antioxidant Effects of Ginkgolides and Bilobalide Against Cerebral Ischemia Injury by Activating the Akt/Nrf2 Pathway In Vitro and In Vivo . Cell Stress Chaperones. 24 (2), 441–452. 10.1007/s12192-019-00977-1
    1. Lu L., Wang S., Fu L., Liu D., Zhu Y., Xu A. (2016). Bilobalide Protection of Normal Human Melanocytes from Hydrogen Peroxide-Induced Oxidative Damage via Promotion of Antioxidase Expression and Inhibition of Endoplasmic Reticulum Stress. Clin. Exp. Dermatol. 41, 64–73. 10.1111/ced.12664
    1. Matthews M. K., JR. (1998). Association of Ginkgo Biloba With Intracerebral Hemorrhage. Neurology. 50, 1933–1934. 10.1212/wnl.50.6.1933
    1. Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E. T., et al. (2001). The Proteolytic Activity of Tissue-Plasminogen Activator Enhances NMDA Receptor-Mediated Signaling. Nat. Med. 7 (1), 59–64. 10.1038/83358
    1. Nijders S. T. A. B., Bosker R. J. (1999). Multilevel Analysis. 1st ed. New Delhi: SAGE.
    1. Oberpichler H., Sauer D., Rossberg C., Mennel H. D., Krieglstein J. (1990). PAF Antagonist Ginkgolide B Reduces Postischemic Neuronal Damage in Rat Brain Hippocampus. J. Cereb. Blood Flow Metab. 10 (1), 133–135. 10.1038/jcbfm.1990.17
    1. Pietri S., Maurelli E., Drieu K., Culcasi M. (1997). Cardioprotective and Anti-Oxidant Effects of the Terpenoid Constituents of Ginkgo Biloba Extract (EGb 761). J. Mol. Cell Cardiol. 29 (2), 733–742. 10.1006/jmcc.1996.0316
    1. Rowin J., Lewis S. L. (1996). Spontaneous Bilateral Subdural Hematomas Associated With Chronic Ginkgo Biloba Ingestion. Neurology. 46 (6), 1775–1776. 10.1212/wnl.46.6.1775
    1. Shi C., Wu F., Yew D. T., Xu J., Zhu Y. (2010). Bilobalide Prevents Apoptosis through Activation of the PI3K/Akt Pathway in SH-Sy5y Cells. Apoptosis. 15, 715–727. 10.1007/s10495-010-0492-x
    1. Shi C., Zou J., Li G., Ge Z., Yao Z., Xu J. (2011). Bilobalide Protects Mitochondrial Function in Ovariectomized Rats by Up-Regulation of mRNA and Protein Expression of Cytochrome C Oxidase Subunit I. J. Mol. Neurosci. 45, 69–75. 10.1007/s12031-010-9388-z
    1. Takagi T., Kitashoji A., Iwawaki T., Tsuruma K., Shimazawa M., Yoshimura S., et al. (2014). Temporal Activation of Nrf2 in the Penumbra and Nrf2 Activator-Mediated Neuroprotection in Ischemia-Reperfusion Injury. Free Radic. Biol. Med. 72, 124–133. 10.1016/j.freeradbiomed.2014.04.009
    1. Vale S. (1998). Subarachnoid Haemorrhage Associated With Ginkgo Biloba. Lancet. 352, 36. 10.1016/S0140-6736(05)79516-7
    1. Wei J., Fang W., Sha L., Han D., Zhang R., Hao X., et al. (2013). XQ-1H Suppresses Neutrophils Infiltration and Oxidative Stress Induced by Cerebral Ischemia Injury Both In Vivo and In Vitro . Neurochem. Res. 38, 2542–2549. 10.1007/s11064-013-1176-z
    1. William J., Rabinstein Alejandro A., Ackerson T., Adeoye Opeolu M., Bambakidis Nicholas C., Becker K., et al. (2019). Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 50 (12), e344–e418. 10.1016/j.phymed.2004.02.002
    1. Wu Q. J., Tymianski M. (2018). Targeting NMDA Receptors in Stroke: New Hope in Neuroprotection. Mol. Brain. 11, 15. 10.1186/s13041-018-0357-8
    1. Yang X., Zheng T., Hong H., Cai N., Zhou X., Sun C., et al. (2017). Neuroprotective Effects of Ginkgo Biloba Extract and Ginkgolide B Against Oxygen-Glucose Deprivation/Reoxygenation and Glucose Injury in a New In Vitro Multicellular Network Model. Front. Med. 12, 307–318. 10.1007/s11684-017-0547-2
    1. Yuan L. F., Guo H. L. (2017). Effect and Mechanism of Ginkgolide Injection Combined with Edaravone on Acute Cerebral Infarction. Chin. J. Prim. Med. Pharm. 24 (18), 2820–2823.
    1. Yumiko N., Toru Y., Qian L., Kota S., Yasuyuki O., Ryuta M., et al. (2017). Time-dependent Change of In Vivo Optical Imaging of Oxidative Stress in a Mouse Stroke Model. J. Neurosci. Res. 95, 2030–2039.
    1. Zhao W., Wu C., Dornbos D., 3rd, Li S., Song H., Wang Y., et al. (2020). Multiphase Adjuvant Neuroprotection: A Novel Paradigm for Improving Acute Ischemic Stroke Outcomes. Brain Circ. 6 (1), 11–18. 10.4103/bc.bc_58_19
    1. Zhou H. Y., Chen W. Q., Pan Y. S., Suo Y., Meng X., Li H., et al. (2020). Effect of Sex Differences on Prognosis of Intravenous Thrombolysis: Data From the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China). Stroke Vasc. Neurol. 6 (1), 1015 svn-2020-000351. 10.1136/svn-2020-000351

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅